Yunnan Baiyao Group Cooperates With Huawei for AI Drug Development

July 25, 2022 0 Comments

Yunnan Baiyao Group, a Chinese medicine developer and manufacturer, announced on July 25 its signing of the “Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D,” alongside Shenzhen-based tech giant Huawei.

The post Yunnan Baiyao Group Cooperates With Huawei for AI Drug Development appeared first on Pandaily.

Leave a Reply

Your email address will not be published. Required fields are marked *